Wellington Management Group LLP Sells 9,807 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Wellington Management Group LLP lessened its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 13.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 63,513 shares of the biopharmaceutical company's stock after selling 9,807 shares during the quarter. Wellington Management Group LLP's holdings in TG Therapeutics were worth $1,912,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Vermillion Wealth Management Inc. purchased a new position in shares of TG Therapeutics in the 4th quarter worth about $30,000. Quadrant Capital Group LLC raised its position in TG Therapeutics by 137.1% in the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after acquiring an additional 975 shares during the period. Blue Trust Inc. boosted its stake in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 1,594 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its position in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 1,737 shares during the period. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

TGTX traded down $0.22 on Monday, hitting $39.84. The company's stock had a trading volume of 1,566,383 shares, compared to its average volume of 2,969,748. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48. The firm has a market cap of $6.32 billion, a P/E ratio of -398.36 and a beta of 1.94. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company's 50 day simple moving average is $37.21 and its 200-day simple moving average is $34.69.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same quarter in the prior year, the company earned ($0.07) EPS. The company's revenue was up 90.4% on a year-over-year basis. Analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

TGTX has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.